Current treatment and future prospects of dopa-induced dyskinesias

Drugs of Today

Volumn 51, Issue 5, 2015, Pages 315-329

  Mazzucchi, S ^a   Frosini, D ^a   Bonuccelli, U ^a   Ceravolo, R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Dopaminergic modulation; IPX 066; Levodopa induced dyskinesias; Parkinson's disease

Indexed keywords

ADENOSINE; AMANTADINE; AMPA RECEPTOR; APOMORPHINE; CANNABINOID; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; ENDOCANNABINOID; ETIRACETAM; LEVODOPA; MEMANTINE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; ND 0612; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; QUETIAPINE; SEROTONIN 1A AGONIST; SEROTONIN 1B AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; CARBIDOPA; CARBIDOPA, LEVODOPA DRUG COMBINATION; DELAYED RELEASE FORMULATION; DRUG COMBINATION;

ANGIOGENESIS; CHOLINERGIC SYSTEM; DOPAMINERGIC SYSTEM; DRUG FORMULATION; DRUG RELEASE; GABAERGIC SYSTEM; HUMAN; LEVODOPA-INDUCED DYSKINESIA; MULTICENTER STUDY (TOPIC); PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROTONINERGIC SYSTEM; COMPLICATION; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG COMBINATION; DYSKINESIA, DRUG-INDUCED; METABOLISM; PARKINSON DISEASE; TREATMENT OUTCOME;

AMANTADINE; ANTIPARKINSON AGENTS; CARBIDOPA; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84938567315     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2015.51.5.2313726     Document Type: Review

References (109)

1. Cotzias, G. C., Papavasiliou, P. S., Gellene, R. Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J Med 1969, 280(7):337-45.
2. Schrag, A., Quinn, N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000, 123(Pt. 11):2297-305.
3. Fahn, S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000, 47(4, Suppl. 1):S2-9.
4. Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M., Goetz, C. G. Levodopa-induced dyskinesias. Mov Disord 2007, 22(10):1379-89.
5. Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., Lang, A. E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342(20):1484-91.
6. Hauser, R. A., Rascol, O., Korczyn, A. D. et al. Ten-year followup of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007, 22(16):2409-17.
7. Manson, A., Stirpe, P., Schrag, A. Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis 2012, 2(3):189-98.
8. Calabresi, P., Di Filippo, M., Ghiglieri, V., Tambasco, N., Picconi, B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010, 9(11):1106-17.
9. Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., Brotchie, J. M. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 2013, 65(1):171-222.
10. Goetz, C. G., Nutt, J. G., Stebbins, G. T. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord 2008, 23(16):2398-403.
11. Katzenschlager, R., Schrag, A., Evans, A. et al. Quantifying the impact of dyskinesias in PD: the PDYS-26: a patientbased outcome measure. Neurology 2007, 69(6):555-63.
12. Ory-Magne, F., Corvol, J. C., Azulay, J. P. et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 2014, 82(4):300-7.
13. Ferreira, J. J., Katzenschlager, R., Bloem, B. R. et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013, 20(1):5-15.
14. Olanow, C. W., Obeso, J. A., Stocchi, F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006, 5(8):677-87.
15. Fahn, S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 1999, 56(5):529-35.
16. Fahn, S., Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005, 252(Suppl. 4):IV37-IV42.
17. Cilia, R., Akpalu, A., Sarfo, F. S. et al. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain 2014, 137(Pt. 10):2731-42.
18. Holloway, R. G., Shoulson, I., Fahn, S. et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004, 61(7):1044-53.
19. Chondrogiorgi, M., Tatsioni, A., Reichmann, H., Konitsiotis, S. Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials. Eur J Neurol 2014, 21(3):433-40.
20. Warren Olanow, C., Kieburtz, K., Rascol, O. et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013, 28(8):1064-71.
21. Sharma, J. C., Ross, I. N., Rascol, O., Brooks, D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008, 15(5):493-6.
22. Pezzoli, G., Klersy, C., Cilia, R. et al. Later age at onset in Parkinson's disease over twenty years in an Italian tertiary clinic. Parkinsonism Relat Disord 2014, 20(11):1181-5.
23. Goetz, C. G., Pal, G. Initial management of Parkinson's disease. BMJ 2014, 349: g6258.
24. Group, P. D. M. C., Gray, R., Ives, N. et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014, 384(9949):1196-205.
25. Fox, S. H., Lang, A. E. 'Don't delay, start today': delaying levodopa does not delay motor complications. Brain 2014, 137(Pt. 10):2628-30.
26. Lieberman, A., Gopinathan, G., Miller, E., Neophytides, A., Baumann, G., Chin, L. Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease. Eur Neurol 1990, 30(2):75-8.
27. Tambasco, N., Simoni, S., Marsili, E. et al. Clinical aspects and management of levodopa-induced dyskinesia. Parkinsons Dis 2012, 2012:745947.
28. Poewe, W., Antonini, A. Novel formulations and modes of delivery of levodopa. Mov Disord 2015, 30(1):114-20.
29. Hauser, R. A., Hsu, A., Kell, S. et al. Extended-release carbidopalevodopa (IPX066) compared with immediaterelease carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013, 12(4):346-56.
30. Le Witt, P., Friedman, H., Giladi, N., et al. Accordion pill carbidopa/levodopa for improved symptomatic treatment of advanced Parkinson's disease. 16th Int Congr Parkinson's Dis Mov Disord (June 17-21, Dublin) 2012, Abst 408.
31. Antonini, A., Yegin, A., Preda, C., Bergmann, L., Poewe, W., investigators, G.s., coordinators Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 2015, 21(3):231-5.
32. Deleu, D., Hanssens, Y., Northway, M. G. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004, 21(11):687-709.
33. Cenci, M. A. Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications. Front Neurol 2014, 5:242.
34. Meco, G., Stirpe, P., Edito, F., Purcaro, C., Valente, M., Bernardi, S., Vanacore, N. Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study. J Neural Transm 2009, 116(7):881-4.
35. Rascol, O., Bronzova, J., Hauser, R. A., Lang, A. E., Sampaio, C., Theeuwes, A., van de Witte, S. V. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord 2012, 18(4):370-6.
36. Brusa, L., Orlacchio, A., Stefani, A., Galati, S., Pierantozzi, M., Iani, C., Mercuri, N. B. Tetrabenazine improves levodopainduced peak-dose dyskinesias in patients with Parkinson's disease. Funct Neurol 2013, 28(2):101-5.
37. Schwab, R. S., England, A. C., Jr., Poskanzer, D. C., Young, R. R. Amantadine in the treatment of Parkinson's disease. JAMA 1969, 208(7):1168-70.
38. Verhagen Metman, L., Del Dotto, P., van den Munckhof, P., Fang, J., Mouradian, M. M., Chase, T. N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998, 50(5):1323-6.
39. Rascol, O., Brooks, D. J., Melamed, E. et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, doubleblind, parallel-group trial. Lancet 2005, 365(9463):947-54.
40. Thomas, A., Iacono, D., Luciano, A. L., Armellino, K., Di Iorio, A., Onofrj, M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004, 75(1):141-3.
41. Wolf, E., Seppi, K., Katzenschlager, R. et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 2010, 25(10):1357-63.
42. Relja, M., Bozikov, J. De-novo amantadine treatment prevents and delays onset of dyskinesias in Parkinson's disease. 18th Int Congr Parkinson's Dis Mov Disord (June 8-12, Stockholm) 2014, Abst.
43. Pahwa, R., Tanner, C. M., Hauser, R. A. et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Mov Disord 2015, 30(6):788-95.
44. Tronci, E., Fidalgo, C., Zianni, E. et al. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. Neuroscience 2014, 265:245-52.
45. Eggert, K., Squillacote, D., Barone, P. et al. Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov Disord 2010, 25(7):896-905.
46. Rascol, O., Barone, P., Behari, M. et al. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol 2012, 35(1):15-20.
47. Kobylecki, C., Burn, D. J., Kass-Iliyya, L., Kellett, M. W., Crossman, A. R., Silverdale, M. A. Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2014, 20(4):452-5.
48. Kobylecki, C., Hill, M. P., Crossman, A. R., Ravenscroft, P. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Mov Disord 2011, 26(13):2354-63.
49. Ouattara, B., Hoyer, D., Gregoire, L., Morissette, M., Gasparini, F., Gomez-Mancilla, B., Di Paolo, T. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience 2010, 167(4):1160-7.
50. Johnston, T. H., Fox, S. H., McIldowie, M. J., Piggott, M. J., Brotchie, J. M. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1, 3-thiazol-4-yl) ethynyl]pyridine in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther 2010, 333(3):865-73.
51. Rylander, D., Iderberg, H., Li, Q. et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 2010, 39(3):352-61.
52. Morin, N., Gregoire, L., Gomez-Mancilla, B., Gasparini, F., Di Paolo, T. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 2010, 58(7):981-6.
53. Gregoire, L., Morin, N., Ouattara, B. et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 2011, 17(4):270-6.
54. Rascol, O., Fox, S., Gasparini, F., Kenney, C., Di Paolo, T., Gomez-Mancilla, B. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord 2014, 20(9):947-56.
55. Stocchi, F., Rascol, O., Destee, A. et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2013, 28(13):1838-46.
56. Ko, W. K., Pioli, E., Li, Q. et al. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) - lesioned primate model of Parkinson's disease. Mov Disord 2014, 29(6):772-9.
57. Lundblad, M., Usiello, A., Carta, M., Hakansson, K., Fisone, G., Cenci, M. A. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 2005, 194(1):66-75.
58. Dekundy, A., Lundblad, M., Danysz, W., Cenci, M. A. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 2007, 179(1):76-89.
59. Rascol, O., Ferreira, J., Negre-Pages, L. et al. A proof-ofconcept, randomized, placebo-controlled, multiple crossovers (n-of-1) study of naftazone in Parkinson's disease. Fundam Clin Pharmacol 2012, 26(4):557-64.
60. Huot, P., Fox, S. H., Brotchie, J. M. The serotonergic system in Parkinson's disease. Prog Neurobiol 2011, 95(2):163-212.
61. Arai, R., Karasawa, N., Nagatsu, I. Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Brain Res 1996, 706(1):177-9.
62. Carta, M., Carlsson, T., Kirik, D., Bjorklund, A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130(Pt. 7):1819-33.
63. Eskow, K. L., Dupre, K. B., Barnum, C. J., Dickinson, S. O., Park, J. Y., Bishop, C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopainduced dyskinesia in hemiparkinsonian rats. Synapse 2009, 63(7):610-20.
64. Carlsson, T., Carta, M., Winkler, C., Bjorklund, A., Kirik, D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci 2007, 27(30):8011-22.
65. Hammerstad, J. P., Carter, J., Nutt, J. G., Casten, G. C., Shrotriya, R. C., Alms, D. R., Temple, D. Buspirone in Parkinson's disease. Clin Neuropharmacol 1986, 9(6):556-60.
66. Kleedorfer, B., Lees, A. J., Stern, G. M. Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry 1991, 54(4):376-7.
67. Goetz, C. G., Damier, P., Hicking, C. et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a doubleblind placebo-controlled trial. Mov Disord 2007, 22(2):179-86.
68. Munoz, A., Li, Q., Gardoni, F. et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131(Pt 12):3380-94.
69. Svenningsson, P., Rosenblad, C., Af Edholm Arvidsson, K. et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Brain 2015, 138(Pt. 4):963-73.
70. Durif, F., Debilly, B., Galitzky, M. et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebocontrolled study. Neurology 2004, 62(3):381-8.
71. Katzenschlager, R., Manson, A. J., Evans, A., Watt, H., Lees, A. J. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J Neurol Neurosurg Psychiatry 2004, 75(2):295-7.
72. Durif, F., Vidailhet, M., Bonnet, A. M., Blin, J., Agid, Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995, 45(10):1855-8.
73. Bishop, C., George, J. A., Buchta, W. et al. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. Eur J Neurosci 2012, 36(6):2839-48.
74. Mazzucchi, S., Frosini, D., Ripoli, A., Nicoletti, V., Linsalata, G., Bonuccelli, U., Ceravolo, R. Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease. Acta Neurol Scand 2014: Advanced publication.
75. Huot, P., Johnston, T. H., Lewis, K. D. et al. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances LDOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology 2014, 82:76-87.
76. Gomez-Mancilla, B., Bedard, P. J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993, 16(5):418-27.
77. Pourcher, E., Bonnet, A. M., Kefalos, J., Dubois, B., Agid, Y. Effects of etybenzatropine and diazepam on levodopainduced diphasic dyskinesias in Parkinson's disease. Mov Disord 1989, 4(3):195-201.
78. Murata, M., Hasegawa, K., Kanazawa, I., Japan Zonisamide on P. D Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007, 68(1):45-50.
79. Stathis, P., Konitsiotis, S., Tagaris, G., Peterson, D., Valid-Pd Study Group. Levetiracetam for the management of levodopainduced dyskinesias in Parkinson's disease. Mov Disord 2011, 26(2):264-70.
80. Wolz, M., Lohle, M., Strecker, K. et al. Levetiracetam for levodopainduced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial. J Neural Transm 2010, 117(11):1279-86.
81. Wong, K. K., Alty, J. E., Goy, A. G., Raghav, S., Reutens, D. C., Kempster, P. A. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. Mov Disord 2011, 26(8):1552-5.
82. Lyons, K. E., Pahwa, R. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol 2006, 29(3):148-53.
83. Fox, S. H., Henry, B., Hill, M. P., Peggs, D., Crossman, A. R., Brotchie, J. M. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha (2) adrenoceptor antagonist idazoxan. Mov Disord 2001, 16(4):642-50.
84. Colosimo, C., Craus, A. Noradrenergic drugs for levodopainduced dyskinesia. Clin Neuropharmacol 2003, 26(6):299-305.
85. Lewitt, P. A., Hauser, R. A., Lu, M. et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 2012, 79(2):163-9.
86. Meco, G., Fabrizio, E., Di Rezze, S., Alessandri, A., Pratesi, L. Mirtazapine in L-dopa-induced dyskinesias. Clin Neuropharmacol 2003, 26(4):179-81.
87. Pact, V., Giduz, T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 1999, 53(5):1154.
88. Carpentier, A. F., Bonnet, A. M., Vidailhet, M., Agid, Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 1996, 46(6):1548-51.
89. Lim, S. A., Xia, R., Ding, Y. et al. Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia. Neurobiol Dis 2015, 76:67-76.
90. Di Paolo, T., Gregoire, L., Feuerbach, D., Elbast, W., Weiss, M., Gomez-Mancilla, B. AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord 2014, 20(11):1119-23.
91. Zhang, D., Bordia, T., McGregor, M., McIntosh, J. M., Decker, M. W., Quik, M. ABT-089 and ABT-894 reduce levodopainduced dyskinesias in a monkey model of Parkinson's disease. Mov Disord 2014, 29(4):508-17.
92. Hauser, R. A., Shulman, L. M., Trugman, J. M. et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008, 23(15):2177-85.
93. Hodgson, R. A., Bedard, P. J., Varty, G. B. et al. Preladenant, a selective A (2A) receptor antagonist, is active in primate models of movement disorders. Exp Neurol 2010, 225(2):384-90.
94. Mango, D., Bonito-Oliva, A., Ledonne, A. et al. Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice. Exp Neurol 2014, 261:733-43.
95. Pacher, P., Batkai, S., Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58(3):389-462.
96. Howlett, A. C. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002, 68-69:619-31.
97. van der Stelt, M., Fox, S. H., Hill, M., Crossman, A. R., Petrosino, S., Di Marzo, V., Brotchie, J. M. A role for endocannabinoids in the generation of parkinsonism and levodopainduced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J 2005, 19(9):1140-2.
98. Fox, S. H., Henry, B., Hill, M., Crossman, A., Brotchie, J. Stimulation of cannabinoid receptors reduces levodopainduced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2002, 17(6):1180-7.
99. Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P., Crossman, A. R., Brotchie, J. M. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001, 57(11):2108-11.
100. Potts, L. F., Park, E. S., Woo, J. M. et al. Dual kappaagonist/mu-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease. Ann Neurol 2015, 77(6):930-41.
101. Morgese, M. G., Cassano, T., Cuomo, V., Giuffrida, A. Antidyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB (1) and TRPV1 receptors. Exp Neurol 2007, 208(1):110-9.
102. Martinez, A. A., Morgese, M. G., Pisanu, A. et al. Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Neurobiol Dis 2015, 74:295-304.
103. Sammut, S., Dec, A., Mitchell, D., Linardakis, J., Ortiguela, M., West, A. R. Phasic dopaminergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D (1/5) receptor-dependent mechanism. Neuropsychopharmacology 2006, 31(3):493-505.
104. Jenner, P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008, 9(9):665-77.
105. Padovan-Neto, F. E., Echeverry, M. B., Chiavegatto, S., Del-Bel, E. Nitric Oxide Synthase Inhibitor Improves De Novo and Long-Term l-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats. Front Syst Neurosci 2011, 5:40.
106. Bortolanza, M., Cavalcanti-Kiwiatkoski, R., Padovan-Neto, F. E., da-Silva, C. A., Mitkovski, M., Raisman-Vozari, R., Del-Bel, E. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease. Neurobiol Dis 2014, 73 C: 377-87.
107. Del-Bel, E., Padovan-Neto, F. E., Bortolanza, M., Tumas, V., Aguiar, A. S., Jr., Raisman-Vozari, R., Prediger, R. D. Nitric oxide, a new player in L-DOPA-induced dyskinesia? Front Biosci (Elite Ed) 2015, 7:168-92.
108. Munoz, A., Garrido-Gil, P., Dominguez-Meijide, A., Labandeira-Garcia, J. L. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1beta. Exp Neurol 2014, 261:720-32.
109. Schuster, S., Doudnikoff, E., Rylander, D. et al. Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3, 4-dihydroxyphenylalanineinduced dyskinesia. Biol Psychiatry 2009, 65(6):518-26.